Back to dataset

FLS-DB clinical data barnadised

The Fracture Liaison Service Database (FLS-DB) January to December 2024

You're previewing the first 4 rows of this file.

FLS code	FLS name	Data completeness (%)	Total submitted (non spine)	Total submitted (spine)	Total submitted (hip)	Total submitted (non-hip, non-spine)	Estimated caseload (spine)	Percentage submitted (spine)	Percentage submitted (hip)	Percentage submitted (non-hip, non-spine)	Total submitted (under 75) (excluding spine)	Total submitted (over 75) (excluding spine)	Estimated caseload (excluding spine)	Percentage of estimated caseload submitted (all patients) (excluding spine)	Percentage of estimated caseload submitted (under 75)(excluding spine)	Percentage of estimated caseload submitted (over 75)(excluding spine)	Number assessed within 90 days (all patients)	Percentage assessed within 90 days	Number DXA within 90 days (all patients)	Percentage DXA within 90 days (all patients)	Number receiving a falls assessment (all patients)	Number receiving a falls assessment (under 75)	Number receiving a falls assessment (over 75)	Percentage receiving a falls assessment (all patients)	Percentage receiving a falls assessment (under 75)	Percentage receiving a falls assessment (over 75)	Number of patients with a treatment recommendation (all patients)	Number of patients with a treatment recommendation (under 75)	Number of patients with a treatment recommendation (over 75)	Percentage of patients with a treatment recommendation (all patients)	Percentage of patients with a treatment recommendation (under 75)	Percentage of patients with a treatment recommendation (over 75)	Oral bisphosphonates %	Total number of patients receiving bisphosphonates	Zoledronate %	Total number of patients receiving zoledronate	Denosumab %	Total number of patients receiving denosumab	Abaloparatide %	Total number of patients receiving abaloparatide	Teriparatide %	Total number of patients receiving teriparatide	Romosozumab %	Total number of patients receiving romosozumab	Referred to GP %	Total number of patients referred to a GP	Referred for clinical opinion %	Total number of patients referred for clinical opinion	Number of patients due follow up (non-hip fracture)	Number of patients due follow up (non-hip fracture patients) (under 75)	Number of patients due follow up (non-hip fracture patients) (over 75)	Number of patients due follow up (all patients)	Number of patients started strength and balance (non-hip fracture)	Number of patients started strength and balance (non-hip fracture) (under 75)	Number of patients started strength and balance (non-hip fracture) (over 75)	Percentage of patients started strength and balance (non-hip fracture)	Percentage of patients started strength and balance (non-hip fracture) (under 75)	Percentage of patients started strength and balance (non-hip fracture) (over 75)	Number of patients due follow up (hip fracture patients)	Number of patients followed up (all fractures)	Number of patients followed up (hip fractures)	Number of patients followed up (non-hip fractures)	Percentage of patients followed up (all fractures)	Percentage of patients followed up (hip fractures)	Percentage of patients followed up (non-hip fractures)	Number of patients commenced bone therapy by 1st follow up	Percentage of patients commenced bone therapy by 1st follow up	Total number of patients receiving oral bisphosphonates	oral bisphosphonates %	Total number of patients receiving zoledronate	zoledronate %	Total number of patients receiving denosumab	denosumab %	Total number of patients receiving teriparatide	Teriparatide %	Total number of patients receiving romosozumab	Romosozumab %	Total number of patients referred to GP	Referred to GP %	Total number of patients referred for clinical opinion	Referred for clinical opinion %	Number of patients due follow up at 1 year	Number adherent to bone therapy at 12 months	Percentage of patients adherent to bone therapy at 12 months	Total number of patients receiving oral bisphosphonates	Oral bisphosphonates %	Total number of patients receiving zoledronate	Zoledronate %	Total number of patients receiving denosumab	Denosumab %	Total number of patients receiving teriparatide	Teriparatide %	Total number of patients receiving romosozumab	Romosozumab %	Total number of patients referred to a GP	Referred to GP %	Total number of patients referred for clinical opinion	Referred for clinical opinion %
7A2T	HYWEL DDA UHB	50	407	83	151	256	696	12	37	63	167	240	2782	15	12	17	343	70	30	18	17	*	12	3	2	4	184	83	101	38	41	35	39	71	22	41	8	14	0	0	3	*	2	*	1	*	28	51	164	77	87	183	*	*	*	1	1	1	19	83	*	78	45	26	48	49	27	28	15	*	1	*	1	*	1	*	2	0	0	0	0	.	.		.		.		.		.		.		.		.
7A5T	CTM UHB	20	54	154	21	33	698	22	39	61	21	33	2794	2	2	2	127	61	*	11	124	57	67	60	64	56	98	40	58	47	45	49	39	38	3	*	27	26	0	0	5	*	2	*	13	13	11	11	82	37	45	98	*	*	0	2	5	0	16	7	*	*	7	13	6	18	18	6	6	0	0	*	3	*	4	0	0	0	0	0	0	.	.		.		.		.		.		.		.		.
ADD	CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST FLS	100	2139	116	578	1561	503	23	27	73	904	1235	2012	106	90	123	2079	92	700	82	1971	756	1215	87	81	92	1519	386	1133	67	42	85	24	366	52	786	2	24	0	0	1	18	2	27	5	80	14	207	926	304	622	1372	752	247	505	81	81	81	446	1338	440	898	98	99	97	1020	74	244	18	543	40	18	1	6	0	8	1	0	0	0	0	1380	919	67	322	23	321	23	16	1	6	0	6	0	0	0	11	1
AEI	WRIGHTINGTON WIGAN AND LEIGH NHS FOUNDATION TRUST	60	213	*	*	212	336	0	0	100	167	46	1342	16	25	7	181	85	124	71	212	168	44	99	100	96	49	20	29	23	12	63	22	11	0	0	0	0	0	0	0	0	0	0	63	31	14	7	49	20	29	49	*	0	*	8	0	14	0	9	0	9	18		18	23	47	13	27	0	0	0	0	0	0	0	0	0	0	0	0	.	.		.		.		.		.		.		.		.